Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms

American Journal of Epidemiology

Volumn 161, Issue 5, 2005, Pages 483-493

  McGregor, Jessina C ^a,f   Kim, Peter W ^b   Perencevich, Eli N ^a,c   Bradham, Douglas D ^a,c   Furuno, Jon P ^a   Kaye, Keith S ^d   Fink, Jeffrey C ^a,e   Langenberg, Patricia ^a   Roghmann, Mary Claire ^a,c   Harris, Anthony D ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Center for Drug Evaluation and Research   (United States)

^c Health Care Answers   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

Comorbidity; Drug resistance, bacterial; Predictive value of tests; ROC curve; Sensitivity and specificity

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; VANCOMYCIN;

DRUG RESISTANCE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CALIBRATION; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CHRONIC DISEASE SCORE; COMORBIDITY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RISK FACTOR; SCORING SYSTEM; VALIDATION PROCESS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADOLESCENT; ADULT; BALTIMORE; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMORBIDITY; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 20044387606     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi068     Document Type: Article

References (73)

1. Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-72.
2. Memmel H, Kowal-Vern A, Latenser BA. Infections in diabetic burn patients. Diabetes Care 2004;27:229-33.
3. Baillargeon J, Kelley MF, Leach CT, et al. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis 2004;38:e92-5.
4. Naylor AR, Hayes PD, Darke S. A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA. Eur J Vasc Endovasc Surg 2001;21:289-94.
5. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
6. Joels CS, Matthews BD, Sigmon LB, et al. Clinical characteristics and outcomes of surgical patients with vancomycin-resistant enterococcal infections. Am Surg 2003;69:514-19.
7. Gomez-Barreto D, Calderon-Jaimes E, Rodriguez RS, et al. Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin- susceptible strains. Arch Med Res 2000;31:592-8.
8. Morrison L, Stolarek I. Does MRSA affect patient outcomes in the elderly? A retrospective pilot study. J Hosp Infect 2000;45: 169-71.
9. Garau J, Aguilar L, Rodriguez-Creixems M, et al. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy. J Chemother 1999;11:266-72.
10. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003;82: 322-32.
11. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-9.
12. Lautenbach E. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-23.
13. Roghmann MC, Fink JC, Polish L, et al. Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis 1998;32:254-7.
14. Montesinos I, Salido E, Delgado T, et al. Epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital in the Canary Islands. Infect Control Hosp Epidemiol 2003;24:667-72.
15. Campbell AL, Bryant KA, Stover B, et al. Epidemiology of methicillin-resistant Staphylococcus aureus at a children's hospital. Infect Control Hosp Epidemiol 2003;24:427-30.
16. Husni R, Hachem R, Hanna H, et al. Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002;23:102-3.
17. Terpenning MS, Bradley SF, Wan JY, et al. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 1994;42:1062-9.
18. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996;15: 361-87.
20. Harrell FE Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3: 143-52.
21. Moss M, Wellman DA, Cotsonis GA, An appraisal of multivariable logistic models in the pulmonary and critical care literature. Chest 2003;123:923-8.
22. Babyak MA. What you see may not be what you get: a brief, non-technical introduction to overfitting in regression-type models. Psychosom Med 2004;66:411-21.
23. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.
24. Harrell FE Jr, Lee KL, Matchar DB, et al. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985;69:1071-7.
25. Charlson M, Ales KL, Simon R, et al. Why predictive indexes perform less well in validation studies. Arch Intern Med 1987; 147:2155-61.
26. Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 2003;24:890-6.
27. Cosgrove SE, Carmeli Y. Studies of bloodstream infection outcomes: reading between the lines. Infect Control Hosp Epidemiol 2003;24:884-6.
28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
30. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
31. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
32. Iezzoni LI, ed. Risk adjustment for measuring healthcare outcomes. 2nd ed. Chicago, IL: Health Administration Press, 1997.
33. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
34. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303-16, viii.
35. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
36. Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2003;46:63-8.
37. Low DE, Keller N, Barth A, et al. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S133-45.
38. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999;33:283-97.
39. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
40. Harris AD, Smith D, Johnson JA, et al. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340-5.
41. Harris AD, Perencevich E, Roghmann MC, et al. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002;46:854-8.
42. Kim PW, Harris AD, Roghmann MC, et al. Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients. Antimicrob Agents Chemother 2003;47:2882-7.
43. Harris AD, Nemoy L, Johnson JA, et al. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 2004;25:105-8.
44. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. In: Olmstead RN, ed. APIC infection control and applied epidemiology: principles and practice. St. Louis, MO: Mosby, 1996: A1-A20.
45. Harris AD, Samore MH, Lipsitch M, et al. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002;34:1558-63.
46. Harris AD, Samore MH, Carmeli Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. (Letter). Ann Intern Med 2000;133:159.
47. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
48. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
49. Lemeshow S, Hosmer DW Jr. A. review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
50. Diamond GA. What price perfection? Calibration and discrimination of clinical prediction models. J Clin Epidemiol 1992;45: 85-9.
51. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. JAMA 1994;272:1049-55.
52. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8.
53. Roos LL, Stranc L, James RC, et al. Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 1997;32:229-38; discussion 239-42.
54. Ghali WA, Hall RE, Rosen AK, et al. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1996;49:273-8.
55. Melfi C, Holleman E, Arthur D, et al. Selecting a patient characteristics index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiol 1995;48:917-26.
56. Johnston JA, Wagner DP, Timmons S, et al. Impact of different measures of comorbid disease on predicted mortality of intensive care unit patients. Med Care 2002;40:929-40.
57. Putnam KG, Buist DS, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology 2002;13:340-6.
58. Ottenbacher KJ, Smith PM, Illig SB, et al. Comparison of logistic regression and neural networks to predict rehospitalization in patients with stroke. J Clin Epidemiol 2001;54:1159-65.
59. Kizer JR, Berlin JA, Laskey WK, et al. Limitations of current risk-adjustment models in the era of coronary stenting. Am Heart J 2003;145:683-92.
60. Troillet N, Carmeli Y, Venkataraman L, et al. Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients. J Hosp Infect 1999;42:37-43.
61. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094-8.
62. Ostrowsky BE, Venkataraman L, D'Agata EM, et al. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999;159:1467-72.
63. Perencevich EN, Sands KE, Cosgrove SE, et al. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003;9:196-203.
64. Kaye KS, Sands K, Donahue JG, et al. Preoperative drug dispensing as predictor of surgical site infection. Emerg Infect Dis 2001;7:57-65.
65. Leveille SG, Gray S, LaCroix AZ, et al. Physical inactivity and smoking increase risk for serious infections in older women. J Am Geriatr Soc 2000;48:1582-8.
66. Tacconelli E, D'Agata EM, Karchmer AW. Epidemiological comparison of true methicillin-resistant and methicillin-susceptible coagulase-negative staphylococcal bacteremia at hospital admission. Clin Infect Dis 2003;37:644-9.
67. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003;24: 655-61.
68. Harris AD, Karchmer TB, Carmeli Y, et al. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32: 1055-61.
69. Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. Med Care 1999;37: 1128-39.
70. Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 2003;13:698-703.
71. Lamont EB, Christakis NA, Lauderdale DS. Favorable cardiac risk among elderly breast carcinoma survivors. Cancer 2003;98: 2-10.
72. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III. colon cancer. J Clin Oncol 2002;20:3992-8.
73. Wang PS, Walker A, Tsuang M, et al. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000;53:571-8.